Dr. Atul Gupta, FRSC, FRSB, FICS, FICC, Group Leader-ATG Lab
Also known as: Scientist F & Group Leader, Medicinal Chemistry Laboratory, CSIR-CIMAP and Professor at Academy of Scientific and Innovative Research (AcSIR)
Central Institute of Medicinal and Aromatic Plants, CSIR-Central Drug Research Institute
0000-0002-7932-8521
About
As a researcher, I have made significant and original contributions in the area of medicinal chemistry / organic chemistry. During my scientific journey, I have made substantial contributions to developing novel Estrogen Receptor Modulators for the treatment of estrogen-dependent disorders, mainly breast cancer and osteoporosis. To achieve the research objectives, our research group synthesized various new pharmacophores through structural modifications of naturally occurring Benzopyrans, such as daidzein, tambulin, precocene, and their derivatives. My approach is to get selective anticancer agents for breast cancer and anti-osteoporotic agents by targeting Estrogen receptors, more specifically estrogen receptor-β.
Several potent leads have been identified with selective anticancer activity (IC50 = 10nM to 10 μM) and anti-osteoporotic properties at 1 pM concentrations. A few leads have also been obtained with anticancer activity against breast cancer. In an in vivo model, some of these leads showed good and selective anti-breast cancer and anti-osteoporotic effects at a 5mg/kg body weight dose. These leads were non-toxic to albino mice in acute and sub-acute oral toxicity studies. These pharmacophores had affinity to estrogen receptors.
In addition, several synthetic and semisynthetic analogues of chalcones and heterocyclic compounds have also been synthesized as potent antimycobacterial agents (MIC = 3.6 to 25μg/mL).
I have also developed isolation processes for Silymarin and its constituents from Silybum marianum (L.) Gaertn. and Glabridin as antimycobacterial agents from Glycyrrhiza glabra L. and a novel chemical process for vanillin production from eugenol and eugenol-rich essential oils.
I have also developed new synthetic methodologies to modify natural compounds for their target-oriented pharmacological actions and value addition.
Employment
-
Central Institute of Medicinal and Aromatic Plants Scientist-F2008 - Present
Education
-
CSIR-Central Drug Research Institute Doctorate
Projects & Funding
Projects & funding information is unavailable.
Publications (70)
- Molecular Interactions of Precocene Derivatives in Crystal Structures and in Silico Evaluation of Their Binding to Estrogen Receptors Save
- An Update on Total Synthesis and Structural Modifications of Glabridin Save
- Pharmaceutical perspectives of thymoquinone, a lead molecule from black cumin (Nigella sativa L.) with diverse biological targets Save
- Value Addition to Citrus maxima Peels: Extraction and Modification of Naringenin into Hydrazones Derivatives for Anti‐Breast Cancer and Osteogenic Activity via In Vitro and In Silico Studies Save
- Miscellaneous drug combinations in diabetes mellitus Save
- Imidazole-catalyzed construction of bridged bicyclo [3.3.1] ketals via formal [3 + 3]-cycloaddition of naphthols and 2-hydroxyl chromene derivatives Save
- Uncovering the Potential of O‐Prenylated 3‐Aryl‐benzopyran Derivatives as Osteogenic and Cancer Cell Growth Inhibitory Agents Save
- From biosynthesis to therapeutics: A comprehensive review on varied functions of estrogen and selective estrogen receptor modulators Save
- Botany, phytochemistry, pharmacology and ecological status of Rauvolfia Plum. ex. L. (Apocynaceae) from the Southern Western Ghats: A review Save
- 5H-benzo[c]fluorene derivative exhibits antiproliferative activity via microtubule destabilization Save